Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

REHOVOT, Israel and JERSEY CITY, New Jersey, September 24 /PRNewswire/ -- Rosetta Genomics Ltd (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics, announced today its management will present at the Maxim Group Growth Conference in New York City on Tuesday, October 7, 2008. The conference will be held at the Grand Hyatt New York Hotel.

About MicroRNA

LYON, France, September 24 /PRNewswire/ -- Initially scheduled for 15 October, the launch of the serial game AOsphere has been put off until January 2009. http://www.identifiction.com will nonetheless open with a beta version before the end of the year. The creative team will offer its first interactive serial exclusively to those registered.

LONDON, September 24 /PRNewswire/ --

Electronic Ink, a design consultancy dedicated to improving the way people interact with technology, environments and one another, today announced that it has expanded its full-service London office, according to Harold Hambrose, CEO and founder of the 18-year-old firm based in the U.S.

The new London office serves clients throughout Europe, including Microsoft, E.ON UK, British Petroleum, National Grid, AstraZeneca, IBM, GlaxoSmithKline, Sungard and Barclays PLC. Electronic Ink has worked steadily in the UK and Europe since the company was founded in 1990.

SAN DIEGO, September 24 /PRNewswire/ --

ChemBridge Corporation today announced new multi-year research collaboration in discovery chemistry with AstraZeneca. This new alliance follows the previous collaboration between ChemBridge and AstraZeneca that was established in 2006 and successfully completed earlier this year ahead of schedule. In accordance with the new agreement scientists from ChemBridge and AstraZeneca will work together to design and develop a new generation of highly advanced, research intensive small molecule libraries that further enhance AstraZeneca's global drug discovery effort. Further details and financial terms were not disclosed.

BRUSSELS, Belgium, September 24 /PRNewswire/ --

- Theme for 2008 World Diabetes Day - November 14 - is "Diabetes in Children and Adolescents"

BRUSSELS, Belgium, September 24 /PRNewswire/ --

The International Diabetes Federation announced today that it is calling on groups and individuals worldwide to get involved in activities to raise awareness of diabetes in the 50 days leading up to World Diabetes Day on November 14. The theme for this year's campaign is "Diabetes in Children and Adolescents."

CARDIFF, Wales, September 24 /PRNewswire/ --

- Huge Broadband Performance Gap Across European Cities

Epitiro, the broadband communications authority, today published the 'European City Internet Performance Index 2008', a preliminary report based on the company's ongoing research into broadband services across the EU Member States.

The data, derived from testing broadband services from leading ISPs in Amsterdam, Dublin, Lisbon, London, Madrid, Milan, Paris and Zurich, is part of a major customer experience research project by Epitiro to understand the actual broadband service levels delivered to EU consumers and businesses.

The early findings confirm the existence of a 'digital divide' amongst European cities: